相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。KarXT treatment improves cognitive performance in cognitively impaired patients with schizophrenia: a post-hoc analysis of the phase 2 EMERGENT-1 study
C. Sauder et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2021)
The M1/M4 preferring muscarinic agonist xanomeline modulates functional connectivity and NMDAR antagonist-induced changes in the mouse brain
Caterina Montani et al.
NEUROPSYCHOPHARMACOLOGY (2021)
Associations between plasma clozapine/N-desmethylclozapine ratio, insulin resistance and cognitive performance in patients with co-morbid obesity and ultra-treatment resistant schizophrenia
Kenya A. Costa-Dookhan et al.
SCIENTIFIC REPORTS (2021)
Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia
Stephen K. Brannan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Fine Tuning Muscarinic Acetylcholine Receptor Signaling Through Allostery and Bias
Emma T. van der Westhuizen et al.
FRONTIERS IN PHARMACOLOGY (2021)
Acetylcholine prioritises direct synaptic inputs from entorhinal cortex to CA1 by differential modulation of feedforward inhibitory circuits
Jon Palacios-Filardo et al.
NATURE COMMUNICATIONS (2021)
Activation of the mGlu1 metabotropic glutamate receptor has antipsychotic-like effects and is required for efficacy of M4 muscarinic receptor allosteric modulators
Samantha E. Yohn et al.
MOLECULAR PSYCHIATRY (2020)
Heterogeneity and efficacy of antipsychotic treatment for schizophrenia with or without treatment resistance: a meta-analysis
Yuya Mizuno et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Current Advances in Allosteric Modulation of Muscarinic Receptors
Jan Jakubik et al.
BIOMOLECULES (2020)
Muscarinic M1 Receptors Modulate Working Memory Performance and Activity via KCNQ Potassium Channels in the Primate Prefrontal Cortex
Veronica C. Galvin et al.
NEURON (2020)
Disrupted Sleep and Circadian Rhythms in Schizophrenia and Their Interaction With Dopamine Signaling
Anna Ashton et al.
FRONTIERS IN NEUROSCIENCE (2020)
Examining the role of muscarinic M5 receptors in VTA cholinergic modulation of depressive-like and anxiety-related behaviors in rats
Eric J. Nunes et al.
NEUROPHARMACOLOGY (2020)
Modulation of arousal and sleep/wake architecture by M1PAM VU0453595 across young and aged rodents and nonhuman primates
Robert W. Gould et al.
NEUROPSYCHOPHARMACOLOGY (2020)
Molecules and Circuits Implicated in Schizophrenia Provide Leads for Novel Treatments
Ned H. Kalin
AMERICAN JOURNAL OF PSYCHIATRY (2020)
Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse
Joseph T. Coyle et al.
AMERICAN JOURNAL OF PSYCHIATRY (2020)
Relationship of Change in Plasma Clozapine/N-desmethylclozapine Ratio with Cognitive Performance in Patients with Schizophrenia
Royun Park et al.
PSYCHIATRY INVESTIGATION (2020)
Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia
Ivan Pozhidaev et al.
APPLICATION OF CLINICAL GENETICS (2020)
Classics in Chemical Neuroscience: Chlorpromazine
Debra Boyd-Kimball et al.
ACS CHEMICAL NEUROSCIENCE (2019)
GPCR Signaling Regulation: The Role of GRKs and Arrestins
Vsevolod V. Gurevich et al.
FRONTIERS IN PHARMACOLOGY (2019)
Structures of the M1 and M2 muscarinic acetylcholine receptor/G-protein complexes
Shoji Maeda et al.
SCIENCE (2019)
High-Frequency Activation of Nucleus Accumbens D1-MSNs Drives Excitatory Potentiation on D2-MSNs
T. Chase Francis et al.
NEURON (2019)
Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs
Scott A. Hollingsworth et al.
NATURE COMMUNICATIONS (2019)
NMDAR Hypofunction Animal Models of Schizophrenia
Gloria Lee et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Widespread Changes in Positive Allosteric Modulation of the Muscarinic M1 Receptor in Some Participants With Schizophrenia
Shaun Hopper et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2019)
In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M1 Receptor, and Xanomeline, an Agonist of Muscarinic M1/M4 Receptor, in Rodents
Takao Mandai et al.
NEUROSCIENCE (2019)
Schizophrenia
Stephen R. Marder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Muscarinic M1 Receptor Modulation of Synaptic Plasticity in Nucleus Accumbens of Wild-Type and Fragile X Mice
Daniela Neuhofer et al.
ACS CHEMICAL NEUROSCIENCE (2018)
Discovery and Optimization of Potent and CNS Penetrant M5-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold
Aaron M. Bender et al.
ACS CHEMICAL NEUROSCIENCE (2018)
Immunolocalization of muscarinic M1 receptor in the rat medial prefrontal cortex
Satoko Oda et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2018)
Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy
Stuti Verma et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2018)
Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M4 PAM VU0467154
Robert W. Gould et al.
NEUROPHARMACOLOGY (2018)
Physiological roles of CNS muscarinic receptors gained from knockout mice
Morgane Thomsen et al.
NEUROPHARMACOLOGY (2018)
Positive allosteric modulation of M-1 and M-4 muscarinic receptors as potential therapeutic treatments for schizophrenia
Samantha E. Yohn et al.
NEUROPHARMACOLOGY (2018)
Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases
Christian C. Felder et al.
NEUROPHARMACOLOGY (2018)
The use of chemogenetic approaches to study the physiological roles of muscarinic acetylcholine receptors in the central nervous system
Sophie J. Bradley et al.
NEUROPHARMACOLOGY (2018)
Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease
E. P. Lebois et al.
NEUROPHARMACOLOGY (2018)
Low levels of muscarinic M1 receptor-positive neurons in cortical layers III and V in Brodmann areas 9 and 17 from individuals with schizophrenia
Elizabeth Scarr et al.
JOURNAL OF PSYCHIATRY & NEUROSCIENCE (2018)
Management of common adverse effects of antipsychotic medications
T. Scott Stroup et al.
WORLD PSYCHIATRY (2018)
Effects of M1 and M4 activation on excitatory synaptic transmission in CA1
Catherine A. Thorn et al.
HIPPOCAMPUS (2017)
Muscarinic receptor signaling contributes to atypical antipsychotic drug reversal of the phencyclidine-induced deficit in novel object recognition in rats
Masanori Miyauchi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders
Daniel J. Foster et al.
NEURON (2017)
M1 muscarinic activation induces long-lasting increase in intrinsic excitability of striatal projection neurons
Xiaohui Lv et al.
NEUROPHARMACOLOGY (2017)
Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients
Conrad Molins et al.
PSYCHIATRY RESEARCH (2017)
Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model
A. Ghoshal et al.
NEUROPSYCHOPHARMACOLOGY (2016)
Effects of Selective M1 Muscarinic Receptor Activation on Hippocampal Spatial Representations and Neuronal Oscillations
Evan P. Lebois et al.
ACS CHEMICAL NEUROSCIENCE (2016)
Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256
Michael D. Grannan et al.
ACS CHEMICAL NEUROSCIENCE (2016)
Design and optimization of selective azaindole amide M1 positive allosteric modulators
Jennifer E. Davoren et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Peng Li et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2016)
Crystal structures of the M1 and M4 muscarinic acetylcholine receptors
David M. Thal et al.
NATURE (2016)
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia (vol 88, pg 762, 2015)
Weixing Shen et al.
NEURON (2016)
Cholinergic Mesopontine Signals Govern Locomotion and Reward through Dissociable Midbrain Pathways
Cheng Xiao et al.
NEURON (2016)
Antipsychotic-like Effects of M4 Positive Allosteric Modulators Are Mediated by CB2 Receptor-Dependent Inhibition of Dopamine Release
Daniel J. Foster et al.
NEURON (2016)
State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154-Relation to antipsychotic-like drug effects
Robert W. Gould et al.
NEUROPHARMACOLOGY (2016)
Positive Allosteric Modulation of the Muscarinic M1 Receptor Improves Efficacy of Antipsychotics in Mouse Glutamatergic Deficit Models of Behavior
Kwok H. C. Choy et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Role for the M1 Muscarinic Acetylcholine Receptor in Top-Down Cognitive Processing Using a Touchscreen Visual Discrimination Task in Mice
R. W. Gould et al.
ACS CHEMICAL NEUROSCIENCE (2015)
Second-generation antipsychotic effect on cognition in patients with schizophrenia-a meta-analysis of randomized clinical trials
R. E. Nielsen et al.
ACTA PSYCHIATRICA SCANDINAVICA (2015)
Prediction of Working Memory Performance in Schizophrenia by Plasma Ratio of Clozapine to N-Desmethylclozapine
Tarek K. Rajji et al.
AMERICAN JOURNAL OF PSYCHIATRY (2015)
Possible Involvement of Muscarinic Receptors in Psychiatric Disorders: A Focus on Schizophrenia and Mood Disorders
B. Dean et al.
CURRENT MOLECULAR MEDICINE (2015)
Glutamate and dopamine in schizophrenia: An update for the 21st century
Oliver Howes et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Modulation of direct pathway striatal projection neurons by muscarinic M4-type receptors
Teresa Hernandez-Flores et al.
NEUROPHARMACOLOGY (2015)
Muscarinic regulation of dopamine and glutamate transmission in the nucleus accumbens
Jung Hoon Shin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The effect of a muscarinic receptor 1 gene variant on grey matter volume in schizophrenia
Vanessa L. Cropley et al.
PSYCHIATRY RESEARCH-NEUROIMAGING (2015)
Antipsychotic-Like Effect of the Muscarinic Acetylcholine Receptor Agonist BuTAC in Non-Human Primates
Maibritt B. Andersen et al.
PLOS ONE (2015)
M4 mAChR-Mediated Modulation of Glutamatergic Transmission at Corticostriatal Synapses
Tristano Pancani et al.
ACS CHEMICAL NEUROSCIENCE (2014)
Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents
Michael Bubser et al.
ACS CHEMICAL NEUROSCIENCE (2014)
Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia
Maren Carbon et al.
CNS SPECTRUMS (2014)
Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia
Amanda L. Jones et al.
JOURNAL OF NEUROIMMUNOLOGY (2014)
M5 Receptor Activation Produces Opposing Physiological Outcomes in Dopamine Neurons Depending on the Receptor's Location
Daniel J. Foster et al.
JOURNAL OF NEUROSCIENCE (2014)
Direct excitation of parvalbumin-positive interneurons by M1 muscarinic acetylcholine receptors: roles in cellular excitability, inhibitory transmission and cognition
Feng Yi et al.
JOURNAL OF PHYSIOLOGY-LONDON (2014)
Muscarinic acetylcholine receptors: novel opportunities for drug development
Andrew C. Kruse et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Acute and chronic effects of the M1/M4-preferring muscarinic agonist xanomeline on cocaine vs. food choice in rats
Morgane Thomsen et al.
PSYCHOPHARMACOLOGY (2014)
Activation and allosteric modulation of a muscarinic acetylcholine receptor
Andrew C. Kruse et al.
NATURE (2013)
The Muscarinic Acetylcholine Receptor Agonist BuTAC Mediates Antipsychotic-Like Effects via the M4 Subtype
Marla L. Watt et al.
NEUROPSYCHOPHARMACOLOGY (2013)
Cholinergic muscarinic M4 receptor gene polymorphisms: A potential risk factor and pharmacogenomic marker for schizophrenia
Elizabeth Scarr et al.
SCHIZOPHRENIA RESEARCH (2013)
Decreased cortical muscarinic M1 receptors in schizophrenia are associated with changes in gene promoter methylation, mRNA and gene targeting microRNA
E. Scarr et al.
TRANSLATIONAL PSYCHIATRY (2013)
Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse, and Parkinson's Disease
Ditte Dencker et al.
ACS CHEMICAL NEUROSCIENCE (2012)
Tools for GPCR drug discovery
Ru Zhang et al.
ACTA PHARMACOLOGICA SINICA (2012)
A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation
Meritxell Canals et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2012)
Association between genetic variation in a region on chromosome 11 and schizophrenia in large samples from Europe
M. Rietschel et al.
MOLECULAR PSYCHIATRY (2012)
Striatal Dopamine Release Is Triggered by Synchronized Activity in Cholinergic Interneurons
Sarah Threlfell et al.
NEURON (2012)
Acetylcholine as a Neuromodulator: Cholinergic Signaling Shapes Nervous System Function and Behavior
Marina R. Picciotto et al.
NEURON (2012)
Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia
Carrie K. Jones et al.
NEUROPSYCHOPHARMACOLOGY (2012)
Potential action of betel alkaloids on positive and negative symptoms of schizophrenia: A review
Maurizio Coppola et al.
NORDIC JOURNAL OF PSYCHIATRY (2012)
Xanomeline Modulation of the Blood Oxygenation Level-Dependent Signal in Awake Rats: Development of Pharmacological Magnetic Resonance Imaging as a Translatable Pharmacodynamic Biomarker for Central Activity and Dose Selection
Scott Baker et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
The M1/M4 preferring agonist xanomeline reverses amphetamine-, MK801-and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia
Segev Barak et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2011)
M1 and M4 Receptors Modulate Hippocampal Pyramidal Neurons
Sameera Dasari et al.
JOURNAL OF NEUROPHYSIOLOGY (2011)
Antipsychotic Drugs Rapidly Induce Dopamine Neuron Depolarization Block in a Developmental Rat Model of Schizophrenia
Ornella Valenti et al.
JOURNAL OF NEUROSCIENCE (2011)
Involvement of a Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors in the Antipsychotic-like Effects of the M1/M4 Preferring Muscarinic Receptor Agonist Xanomeline
Ditte Dencker et al.
JOURNAL OF NEUROSCIENCE (2011)
Muscarinic Receptor Occupancy and Cognitive Impairment: A PET Study with [11C](+)3-MPB and Scopolamine in Conscious Monkeys
Shigeyuki Yamamoto et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Cholinergic modulation of mesolimbic dopamine function and reward
Gregory P. Mark et al.
PHYSIOLOGY & BEHAVIOR (2011)
Therapeutic potential of β-arrestin- and G protein-biased agonists
Erin J. Whalen et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons
Sarah Threlfell et al.
FRONTIERS IN SYSTEMS NEUROSCIENCE (2011)
Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder
A. Wagg et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Striatal Muscarinic Receptors Promote Activity Dependence of Dopamine Transmission via Distinct Receptor Subtypes on Cholinergic Interneurons in Ventral versus Dorsal Striatum
Sarah Threlfell et al.
JOURNAL OF NEUROSCIENCE (2010)
A Subpopulation of Neuronal M4 Muscarinic Acetylcholine Receptors Plays a Critical Role in Modulating Dopamine-Dependent Behaviors
Jongrye Jeon et al.
JOURNAL OF NEUROSCIENCE (2010)
Facilitation of Long-Term Potentiation by Muscarinic M1 Receptors Is Mediated by Inhibition of SK Channels
Katherine A. Buchanan et al.
NEURON (2010)
The M3-muscarinic receptor regulates learning and memory in a receptor phosphorylation/arrestin-dependent manner
Benoit Poulin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mechanisms Underlying Psychosis and Antipsychotic Treatment Response in Schizophrenia: Insights from PET and SPECT Imaging
O. D. Howes et al.
CURRENT PHARMACEUTICAL DESIGN (2009)
Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice
Marie L. Woolley et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Pharmacological comparison of muscarinic ligands: Historical versus more recent muscarinic M1-preferring receptor agonists
Julia N. Heinrich et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2009)
Direct Interaction of GABAB Receptors with M2 Muscarinic Receptors Enhances Muscarinic Signaling
Stephanie B. Boyer et al.
JOURNAL OF NEUROSCIENCE (2009)
A Selective Allosteric Potentiator of the M1 Muscarinic Acetylcholine Receptor Increases Activity of Medial Prefrontal Cortical Neurons and Restores Impairments in Reversal Learning
Jana K. Shirey et al.
JOURNAL OF NEUROSCIENCE (2009)
Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders
P. Jeffrey Conn et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Altered M1 Muscarinic Acetylcholine Receptor (CHRM1)-Gαq/11 Coupling in a Schizophrenia Endophenotype
Hasib Salah-Uddin et al.
NEUROPSYCHOPHARMACOLOGY (2009)
Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation
Lei Ma et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The role of M1 muscarinic cholinergic receptors in the discriminative stimulus properties of N-desmethylclozapine and the atypical antipsychotic drug clozapine in rats
Adam J. Prus et al.
PSYCHOPHARMACOLOGY (2009)
Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials
Christoph U. Correll et al.
SCHIZOPHRENIA BULLETIN (2009)
Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia
Anantha Shekhar et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Cholinergic modulation of midbrain dopaminergic systems
J. Mena-Segovia et al.
BRAIN RESEARCH REVIEWS (2008)
Novel Selective Allosteric Activator of the M1 Muscarinic Acetylcholine Receptor Regulates Amyloid Processing and Produces Antipsychotic-Like Activity in Rats
Carrie K. Jones et al.
JOURNAL OF NEUROSCIENCE (2008)
M1 muscarinic Agonists target major hallmarks of Alzheimer's disease the pivotal role of brain M1 receptors
Abraham Fisher
NEURODEGENERATIVE DISEASES (2008)
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia
W. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Evaluation of N-desmethylclozapine as a potential antipsychotic -: Preclinical studies
Sridhar Natesan et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Wash-resistantly bound xanomeline inhibits acetylcholine release by persistent activation of presynaptic M2 and M4 muscarinic receptors in rat brain
E. Machova et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia
Elizabeth Scarr et al.
BIOLOGICAL PSYCHIATRY (2007)
Time course of the antipsychotic effect and the underlying behavioral mechanisms
Ming Li et al.
NEUROPSYCHOPHARMACOLOGY (2007)
M1 muscarinic agonists target major hallmarks of Alzheimer's disease - an update
Abraham Fisher
CURRENT ALZHEIMER RESEARCH (2007)
Towards a muscarinic hypothesis of schizophrenia
T. J. Raedler et al.
MOLECULAR PSYCHIATRY (2007)
Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development
Juergen Wess et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Long-term wash-resistant effects of brief interaction of xanomeline at the M1 muscarinic receptor
Kayla C. De Lorme et al.
NEUROSCIENCE LETTERS (2006)
Loss of M5 muscarinic acetylcholine receptors leads to cerebrovascular and neuronal abnormalities and cognitive deficits in mice
Runa Araya et al.
NEUROBIOLOGY OF DISEASE (2006)
Quantitative analysis of muscarinic acetylcholine receptor homo- and heterodimerization in live cells - Regulation of receptor down-regulation by heterodimerization
JC Goin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
No change in cortical muscarinic M2, M3 receptors or [35S]GTPγS binding in schizophrenia
E Scarr et al.
LIFE SCIENCES (2006)
N-desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of MI muscarinic receptors
Z Li et al.
NEUROPSYCHOPHARMACOLOGY (2005)
Persistent binding and functional antagonism by xanomeline at the muscarinic M5 receptor
MKO Grant et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Size of burden of schizophrenia and psychotic disorders
W Rössler et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders
K Zavitsanou et al.
BRAIN RESEARCH BULLETIN (2005)
A systematic review of the prevalence of schizophrenia
S Saha et al.
PLOS MEDICINE (2005)
The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs:: is M1 agonism a pre-requisite for mimicking clozapine's actions?
MA Davies et al.
PSYCHOPHARMACOLOGY (2005)
Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats
CK Jones et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Muscarinic receptor stimulation reduces NMDA responses in CA3 hippocampal pyramidal cells via Ca2+-dependent activation of tyrosine phosphatase
AA Grishin et al.
NEUROPHARMACOLOGY (2005)
Investigation of M1/M4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder
Z Katerina et al.
NEUROPSYCHOPHARMACOLOGY (2004)
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine
DM Weiner et al.
PSYCHOPHARMACOLOGY (2004)
M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission:: relevance to the pathophysiology and treatment of related central nervous system pathologies
ET Tzavara et al.
FASEB JOURNAL (2004)
M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity
T Seeger et al.
JOURNAL OF NEUROSCIENCE (2004)
N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity
C Sur et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders
S Tanaka et al.
JOURNAL OF NEUROIMMUNOLOGY (2003)
The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys
MB Andersen et al.
NEUROPSYCHOPHARMACOLOGY (2003)
Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system
FP Bymaster et al.
NEUROCHEMICAL RESEARCH (2003)
Selective cognitive dysfunction in acetylcholine M-1 muscarinic receptor mutant mice
SG Anagnostaras et al.
NATURE NEUROSCIENCE (2003)
Association of muscarinic M1 receptor genetic polymorphisms with psychiatric symptoms and cognitive function in schizophrenic patients
DL Liao et al.
NEUROPSYCHOBIOLOGY (2003)
Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice
WL Zhang et al.
JOURNAL OF NEUROSCIENCE (2002)
Global epidemiology of areca nut usage
PC Gupta et al.
ADDICTION BIOLOGY (2002)
Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice
DJ Gerber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex
KW Perry et al.
BIOLOGICAL PSYCHIATRY (2001)
Effects of chewing betel nut (Areca catechu) on the symptoms of people with schizophrenia in Palau, Micronesia
RJ Sullivan et al.
BRITISH JOURNAL OF PSYCHIATRY (2000)
分享论文
